Loading
A phase 1/2 trial of BLU-924 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Blueprint Medicines Corporation, now recruiting.
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations is a phase 1/2 interventional study registered as NCT07629960 by Blueprint Medicines Corporation, with 265 participants planned, started 2026-06-04 and due to reach its primary completion in 2029-09. Interventions recorded: BLU-924.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/